Amgen Inc. $AMGN Stock: Talbot Financial LLC Raises Position

Talbot Financial LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,875 shares of the medical research company’s stock after acquiring an additional 1,452 shares during the period. Amgen accounts for approximately 1.9% of Talbot Financial LLC’s portfolio, making the stock its 17th biggest holding. Talbot Financial LLC’s holdings in Amgen were worth $26,081,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Rational Advisors Inc. increased its position in shares of Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after acquiring an additional 24 shares in the last quarter. Beacon Financial Advisory LLC lifted its holdings in shares of Amgen by 2.0% during the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after acquiring an additional 25 shares in the last quarter. James T. Borello RIA boosted its position in Amgen by 13.6% during the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after purchasing an additional 25 shares during the period. Sweeney & Michel LLC boosted its position in Amgen by 0.5% during the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock worth $2,162,000 after purchasing an additional 25 shares during the period. Finally, Legacy Financial Advisors Inc. increased its holdings in Amgen by 0.8% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after purchasing an additional 26 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Down 1.1%

Shares of AMGN stock traded down $4.56 on Monday, hitting $427.93. The stock had a trading volume of 937,316 shares, compared to its average volume of 2,748,843. The firm has a market capitalization of $231.35 billion, a price-to-earnings ratio of 26.58, a P/E/G ratio of 3.17 and a beta of 0.41. The stock’s 50 day moving average is $415.54 and its 200-day moving average is $374.94. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the previous year, the firm posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts expect that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wells Fargo & Company cut their price objective on Amgen from $435.00 to $430.00 and set an “equal weight” rating on the stock in a research report on Monday, October 12th. Morgan Stanley decreased their target price on Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 7th. BMO Capital Markets decreased their target price on Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research report on Monday, October 12th. Jefferies Financial Group reiterated a “hold” rating and issued a $410.00 target price on shares of Amgen in a research note on Wednesday, September 23rd. Finally, TD Cowen raised their target price on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $387.93.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Australia’s Pharmaceutical Benefits Advisory Committee conditionally backed Amgen’s cancer treatment IMDELLTRA, a regulatory and commercial milestone that could improve the drug’s access and revenue prospects in the Australian market. PBAC conditionally backs IMDELLTRA
• Positive Sentiment: Exchange-traded funds purchased approximately $19.4 million of Amgen shares on October 15, signaling institutional demand and potentially providing technical support for the stock. ETFs Bought $19.4 Million of Amgen
• Positive Sentiment: Wall Street Zen upgraded its rating on Amgen, adding to the favorable analyst commentary surrounding the company. Amgen stock rating upgraded
• Neutral Sentiment: Amgen continues to attract elevated investor attention, although the report primarily reviews existing facts and factors affecting the company rather than introducing a new fundamental catalyst. Amgen attracting investor attention
• Neutral Sentiment: Analyst coverage highlights Amgen among healthcare companies but does not identify a specific new earnings estimate, target-price change or business announcement. Analysts offer insights on Amgen
• Negative Sentiment: Investors are questioning Amgen’s growth outlook. While its established medicines generate substantial cash and its newer treatments offer promise, the company must demonstrate accelerating growth to support a premium valuation after a strong run toward its 12-month high. Amgen has the drugs and the dividend, now it needs growth

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.